Latest Myeloproliferative disease Stories
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
SINGAPORE, Dec. 6, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens.
Company to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression.
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type.
WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A.
SAN DIEGO, June 30 /PRNewswire/ -- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN; NYSE: SNY).
SINGAPORE, June 9 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S.
SINGAPORE and EMERYVILLE, Calif., May 4 /PRNewswire-FirstCall/ -- S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc.
FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...
- The governor of a province or people.